



**SDI FINAL EVALUATION FORM 1.1**

**PART 1:**

Journal Name:	<a href="#">British Journal of Pharmaceutical Research</a>
Manuscript Number:	2013_BJPR_4865
Title of the Manuscript:	<b>Study of the hypoglycemic effect of Tamarindus indica Linn. seeds on normal and diabetic model rats</b>

**PART 2:**

<b>FINAL EVALUATOR'S comments on revised paper (if any)</b>	<b>Authors' response to final evaluator's comments</b>
<p>Line 62, GOD-POD should be written out in full and abbreviated in bracket because it is being used for the first time.</p> <p>Line 71, Type-II rats? Small t not capital T</p> <p>Line 88, characteristic not characters</p> <p>Line 90, pharmaceutical not pharmaceutic</p> <p>Line 212, when compared when compared? duplicate</p> <p>The authors responded, "Rats were kept fasting for 36h so that no food particle may remain in the gut that may hamper in the study". I wanted to know why the authors fasted the animals for so long. 16 – 24 hours fasting is sufficient.</p> <p>Regarding my comments, "The authors did not discuss the lack of antihyperglycemic effect of T. indica in type 1 diabetic rats. The authors should endeavour to provide scientific explanations for this discrepancy in the antihyperglycemic effect of T. indica in type 1 and type 2 diabetic rats". The authors did not include their responses/explanations in the Discussion section of the manuscript. The authors should do that.</p>	

**Note: Anonymous Reviewer**